FIELD: biotechnology.
SUBSTANCE: presented group of inventions can be used in medicine. There are disclosed modified oligonucleotides capable of inhibition of double homeobox 4 (DUX4) gene expression.
EFFECT: invention can be used in treating diseases associated with abnormal expression of said gene in an individual, in particular, in antisense gene therapy of facioscapulohumeral muscular dystrophy (FSHD), B-cell acute lymphocytic leukemia, differentiated round-cell sarcoma and fetal rhabdomyosarcoma.
29 cl, 6 dwg, 5 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
FACTOR 11 EXPRESSION MODULATION | 2009 |
|
RU2535964C2 |
ANTISENSE MODULATION OF GCGR EXPRESSION | 2012 |
|
RU2598709C2 |
COMPOSITIONS FOR MODULATING EXPRESSION OF SOD-1 | 2015 |
|
RU2704619C2 |
COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DYSTROPHIC MIOTONIN-PROTEINKINASE (DMPK) | 2014 |
|
RU2690333C2 |
MODULATION OF FACTOR 11 EXPRESSION | 2014 |
|
RU2739594C2 |
MODULATION OF ANDROGEN RECEPTOR EXPRESSION | 2013 |
|
RU2670486C9 |
MODULATING EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2014 |
|
RU2706964C2 |
MODULATORS OF COMPLEMENT FACTOR B | 2014 |
|
RU2662967C2 |
COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2824214C1 |
COMPOSITIONS FOR MODULATION OF ATAXIN 2 EXPRESSION | 2015 |
|
RU2702838C2 |
Authors
Dates
2024-12-02—Published
2020-03-27—Filed